Seattle Genetics gets exclusive global rights to Immunomedics' IMMU132 for solid tumors; deal ends
Executive Summary
Immunomedics Inc. granted Seattle Genetics Inc. exclusive global rights to develop, fund, manufacture, and sell IMMU132 (sacituzumab govitecan) for solid tumors. Immunomedics retains the right to co-promote in the US (if it participates in 50% of the sales efforts).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice